Acer Therapeutics to Participate in August and September 2022 Investor Conferences
August 23 2022 - 8:30AM
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company
focused on the acquisition, development and commercialization of
therapies for serious, rare and life-threatening diseases with
significant unmet medical needs, today announced that Acer’s
management team will virtually present at, and participate in, the
upcoming Gilmartin Group Emerging Growth Company Showcase and H.C.
Wainwright 24th Annual Global Investment Conference.
Conference: Gilmartin Group Emerging Growth
Company ShowcaseFormat: Recorded corporate
presentation Date and Time: Recorded presentation
available at 10:30 am ET, August 31, 2022
Register:
https://gilmartin-emerging-growth-conference.open-exchange.net/registration
Webcast:
https://kvgo.com/corporate-services/acer-therapeutics-aug-2022
Conference: H.C. Wainwright 24th Annual Global
Investment ConferenceFormat: On-demand recorded
corporate presentation and one-on-one virtual meetings Date
and Time: On-demand corporate presentation available
beginning at 7 am ET, September 12, 2022 Webcast:
https://journey.ct.events/view/09133963-6072-4f07-864c-3ed9b50db443
About Acer Therapeutics Inc.Acer is a
pharmaceutical company focused on the acquisition, development and
commercialization of therapies for serious rare and
life-threatening diseases with significant unmet medical needs.
Acer’s pipeline includes four investigational programs: ACER-001
(sodium phenylbutyrate) for treatment of various inborn errors of
metabolism, including urea cycle disorders (UCDs) and Maple Syrup
Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced
Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of
vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed
type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a
host-directed therapy against a variety of viruses, including
cytomegalovirus, Zika, dengue, Ebola and COVID-19. For more
information, visit www.acertx.com.
Corporate and IR ContactJim DeNikeAcer
Therapeutics Inc.jdenike@acertx.com+1-844-902-6100
Nick ColangeloGilmartin
Groupnick@gilmartinIR.com+1-332-895-3226
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Acer Therapeutics (NASDAQ:ACER)
Historical Stock Chart
From Jul 2023 to Jul 2024